retatrutide progress Thailand retatrutide #elililly #retatrutide #weightloss #obesitycare

Levy says GLP-1s, when prescribed correctly, are fantastic for treating obesity

How Dose Decisions Relate to GLP-1 Microdosing in Midlife Hormonal changes during perimenopause and menopause can influence insulin sensitivity, appetite regulation, and medication tolerance

Retatrutide is an investigational triple incretin receptor agonist targeting GLP-1, GIP, and glucagon receptors to reduce appetite and body weight, while tesamorelin is a growth hormone-releasing hormone analogue that stimulates pituitary GH release to reduce visceral fat, primarily in HIV-positive patients with lipodystrophy

This beneficial effect is evident in the G protein-biased agonist Exendin-phe1, derived from a single phenylalanine substitution at position 1 in Exenatide, which displays improved receptor recycling, reduced receptor desensitization, and sustained incretin-stimulated insulin secretion (Jones et al., 2018)

Pleiotropic effects of GLP1 and analogs on cell signaling, metabolism, and function